

Cardiovascular Disease

Lumanity and the PHARMO Institute are partnering to deliver research insights in Cardiovascular Disease

Disease & Treatment Characterization

Including but not limited to:

- Diagnoses and symptoms (International Classification of Primary Care [ICPC] codes)
 - Myocardial infarction
 - Angina pectoris
 - Stroke
 - Limb ischemia
- Test results (BMI, blood pressure, LDL and HDL, triglyceride and total cholesterol)
- Health indicators (smoking and physical fitness)

Treatment Patterns, Burden of Disease, & Healthcare Resource Utilization

- Drug utilization
 - Lipid lowering treatment patterns
 - Adherence/persistence
 - Co-medication (e.g., hypertensive, anti-thrombotic, and anti-diabetic treatments)
 - Medical device use
- Healthcare resource utilization
 - Medication use
 - GP visits (including emails, phone calls, and home visits)
 - Hospitalizations

Comparative Effectiveness, Safety, & Tolerability

- Safety outcomes
 - Cardiovascular outcomes
- Drug effectiveness
 - LDL and HDL cholesterol
- Mortality, pathology
- Social demographics



What makes us different



High patient counts in Cardiovascular Disease

>800,000 Ischemic Heart Disease

- >80,000 Heart Failure
- >100,000 Stroke



A unique, longitudinal, and clinically rich dataset

- 2002 onwards (20+ years)
- Ability to follow through multiple healthcare settings
- Data regularly updated and expanded to include new patients and follow-up information

About PHARMO



The PHARMO Institute is an **independent, global leader** in drug safety and outcomes research



The Netherlands has an excellent healthcare system and is a major hub for clinical trials



The **PHARMO Data Network** offers **multi-setting, longitudinal, clinically rich data** with exceptional curation and linkages to hospitals and national registers



Dutch data is **representative of Western Europe** and can be used in global studies as a **robust proxy** or complement to EU-5



As a founding member of SIGMA Consortium, we can access diverse sources of **pan-European real world data (RWD)** on **>100 million patients**



Our capabilities and experience enable us to deliver on a **wide range of real world evidence (RWE) use cases**



⇒ Why choose us?

Lumantity can be counted on for service and quality. We utilize proven processes supported by technologically advanced resources to produce high-quality services, with guaranteed satisfaction.